Abstract: The present invention relates to controlled release compositions of galantamine, processes to prepare the compositions, their in-vitro release profiles and method of use and method of treatment using the said compositions.

Abstract: Stable and palatable taste masked pharmaceutical compositions of substituted benzhydrylpiperazines and processes for preparing them.

Abstract: Stable pharmaceutical compositions of desloratadine or pharmaceutically acceptable salts in combination with one or more therapeutically active compounds.

Abstract: Pharmaceutical compositions of metoprolol or a salt have water-insoluble inorganic cores such as dibasic calcium phosphate having the drug deposited thereon, optionally with one or more hydrophilic or hydrophobic polymers or mixtures thereof, and an outer coating of a polymer blend utilizing groups of polymers having opposing wettability characteristics.

Abstract: A pharmaceutical composition for controlled drug delivery comprising a ?-lactam antibiotic or its pharmaceutically acceptable hydrates, salts or esters, and one or more carbomers. The above ?-lactam antibiotics formulation avoids the limitations of known ?-lactam controlled release form which are found to be either complex and/or cost-extensive to obtain requiring multiphase and/or selective coatings or fail to achieve the desired controlled release for once daily dosage form. Importantly, in the ?-lactam antibiotic form of the above the rate-controlling polymer wherein the Cmax of the formulation is substantially the same as that of a single dose of the immediate release formulation. Also advantageously the formulation achieves a rate controlling polymer wherein the T>MIC for the formulation is more than 17 hours when the MIC is 0.25 mcg/ml and more than 10 hours when the MIC is 2 mcg/ml.

Abstract: Stabilized pharmaceutical solid composition of ACE inhibitor comprising an ACE inhibitor and a selective dosage formulation thereof comprising of meglumine. The ACE inhibitor selectively combined with a dosage form including essentially the meglumine is surprisingly found to avoid the degradation of ACE inhibitor by such dosage forms especially the commonly used pharmaceutical excepients. In particular, the presence of the meglumine in the dosage form for the active along with the active ACE inhibitor surprisingly avoid the degradation of the ACE inhibitor due to a) cyclization via internal nucleophilic attack to form substituted diketopiperazines, b) hydrolysis of the side chain ester group, and c) oxidation to form products having often unwanted coloration.

Abstract: The present invention provides a method and composition for expression of multiple genes from a polycistronic message in transgenic plants using genetic elements derived from the peanut chlorotic streak caulimovirus promoter-leader sequence and antisense sequence of PC1SV ORF VII. Also provided are compositions and methods for intron-mediated enhanced and regulated expression of genes in transgenic plants.

Abstract: A method of treatment to avoid bioavailability food effects and improve bioavailability variability, by administering a pharmaceutical dosage form containing a pharmaceutical active agent and a disintegrant in a core, a swellable coating surrounding the core, and an optional enteric coating surrounding the swellable coating.

Abstract: This invention relates to a process of mixing of crystalline cefuroxime axetil with amorphous cefuroxime axetil for the preparation of a bioavailable oral dosage form comprising of amorphous cefuroxime axetil containing from 7 to 25% crystalline cefuroxime axetil.

Abstract: The present invention provides materials and methods related to causing insect resistance in plants. Specifically, the present invention provides nucleic acid compounds which encode a teratocyte secreted protein (TSP) which is capable of causing inhibition of growth and developmental arrest in Lepidoptera larvae. Cells and plants (including plant parts, seeds, embryos, etc.) comprising the nucleic acid compounds are also within the scope of the present invention. The present invention also provides amino acid compounds encoded by the nucleic acid compounds of the present invention, as well as methods to induce larval developmental arrest, methods to produce the nucleic acid and amino acid compounds, and methods to inhibit crop damage due to Lepidoptera infestation.

Abstract: This invention relates to a bioavailable oral dosage form comprising of amorphous cefuroxime axetil containing from 7 to 25% crystalline cefuroxime axetil.

Abstract: A stable solid pharmaceutical composition in the form of tablets or capsules is disclosed including enalapril maleate as active ingredient and pharmaceutically acceptable excipients wherein at least one excipient is maleic acid or other edible desiccants.